Sun Pharma launches Ilumya for plaque psoriasis
Sun Pharmaceutical Industries is offering Ilumya (tildrakizumab-asmn) 100 mg/mL for moderate-to-severe plaque psoriasis.
Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
“The availability of Ilumya is an important milestone for Sun Pharma as we expand our specialty medicine portfolio in the U.S. Ilumya offers a new, safe and effective treatment option for people who are still struggling to manage their moderate-to-severe plaque psoriasis,” Sun Pharma, North America CEO Abhay Gandhi said in a statement. “We understand the importance of patient and physician choice, and are committed to making Ilumya among the most cost-effective treatments on the market today.”
Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
“The availability of Ilumya is an important milestone for Sun Pharma as we expand our specialty medicine portfolio in the U.S. Ilumya offers a new, safe and effective treatment option for people who are still struggling to manage their moderate-to-severe plaque psoriasis,” Sun Pharma, North America CEO Abhay Gandhi said in a statement. “We understand the importance of patient and physician choice, and are committed to making Ilumya among the most cost-effective treatments on the market today.”